Factores de riesgo para cáncer de cuello uterino

La carga de la enfermedad en Colombia. Bogotá: Ministerio de Salud; 1994.

Haddad N, da Silva MB. Mortalidade por neoplasmas em mulheres em idade reprodutiva - 15 a 49 anos - no estado de São Paulo, Brasil, de 1991 a 1995. Rev Assoc Med Bras 2001;47:221-30.

Bosch FX, Lorincz A, Muñoz N, Meijer CJL, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.

Medina MR. Atlas de mortalidad por cáncer en Colombia 1990. Bogotá: Instituto Nacional de Cancerología; 1994.

Capurro I, Rojo JA, Pino T, Vásquez C, Garay J, Venegas M. Programa de detección y control de cáncer de cuello uterino en servicio salud Araucania Sur. Rev Chil Obstet Ginecol 2002;67:114-20.

Wright TC, Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ; ASCCP-Sponsored Consensus Conference. 2001 consensus guidelines for the management of women with cervical cytology abnormalities. JAMA 2002;287:2120-9.

Shanta V, Krishnamurthi S, Gajalakshmi CK, Swaminathan R, Ravichandran K. Epidemiology of cancer of cervix: global and national perspective. J Indian Med Assoc 2000;98:49-52.

Sánchez V, Izquierdo A, Beltrán M, Viladiu P. Epidemiología del cáncer invasor de cerviz en el àrea sanitaria de Girona durante el período 1980-1989. Registro poblacional de cáncer de Gerona. Rev Esp Salud Publica 1997;71:19-26.

Sherris J, Herdman C, Elias C. Beyond our borders. Cervical cancer in the developing world. West J Med 2001;175:231-3.

Registro Poblacional de Cáncer del Área Metropolitana de Bucaramanga. Incidencia de cáncer en el Área Metropolitana de Bucaramanga, 2000-2001. UNAB; 2003.

Viikki M, Pukkala E, Hakama M. Risk of cervical cancer after a negative Pap smear. J Med Screen 1999;6:103-7.

Hernández-Avila M, Lazcano-Ponce EC, Alonso de Ruiz P, López-Carrillo L, Rojas R. Evaluación del programa de detección oportuna de cáncer de cuello uterino en la ciudad de México. Un estudio epidemiológico de casos y controles con base poblacional. Gac Méd Méx 1994;130:201-9.

Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organ 2001;79:954-62.

Gómez J. Costos y calidad de la prueba de detección oportuna del cáncer cervicouterino en una clínica y en una organización no gubernamental. Salud pública Méx 2001;43:279-88.

Invasive cervical cancer amog hispanic and non-hispanic women – United States, 1992-1999. MMWR Morb Mortal Wkly Rep 2002;51:1067-70.

Hakama M. Trends in the incidence of cervical cancer in the Nordic countries. In: Magnus K (ed). Trends in cancer incidence: causes and practical implications. Washington: Hemisphere Pub. Corp.; 1982. p. 279-92.

Sigurdson K, Adalsteinsson S, Ragnarsson J. Trends in cervical and breast cancer in Iceland. A statistical evaluation of trends in incidence and mortality for the period 1955-1989. Their relation to screening and prediction to the year 2000. Int J Cancer 1991;48:523-8.

Ehrmann RL. Benign to malignant progression in cervical squamous epithelium. New York: Igauku-Shoin; 1994.

Raab SS, Steiner AL, Hornberger J. The cost-effectiveness of treating women with a cervical vaginal smear diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1998;179:411-20.

Disaia PJ, Creasman WT. Clinical gynecologic oncology. 5th ed. St. Louis: Mosby; 1999.

Mandelblatt JS, Kanetsky P, Eggert L, Gold K. Is HIV infection a cofactor for cervical squamous cell neoplasia? Cancer Epidemiol Biomarkers Prev 1999;8:97-106.

Wang SS, Wheeler CM, Hildesheim A, Schiffman M, Herrero R, Bratti MC, et al. Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J Infect Dis 2001;184:1310-4.

Apgar BS, Brotzman G. HPV testing in the evaluation of the minimally abnormal Papanicolau smear. Am Fam Physician 1999;59:2794-801.

Sellors JW, Mahony JB, Kaczorowski J, Lytwyn A, Bangura H, Chong S, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. CMAJ 2000;165:503-8.

Sellors JW, Lorincz AT, Mahony JB, Mielzynska I, Lytwyn A, Roth P, et al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. CMAJ 2000;165:513-8.

Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Eng J Med 1998;338:423-8.

Lytwyn A, Sellors JN. Sexually transmitted human papillomavirus: current concepts and control issues. Can J Hum Sex 1997;6:113-26.

Hart KW, Williams OM, Thelwell N, Fiander AN, Brown T, Borysiewicz LK, et al. Novel method for detection, typing and quantification of human papillomaviruses in clinical samples. J Clin Microbiol 2001;39:3204-12.

Molano M, Posso HJ, Weiderpass E, van den Brule AJ, Ronderos M, Franceshi S, et al. Prevalence and determinants of HPV infection among Colombian women with normal citology. Br J Cancer 2002;87:324-33.

Nonenmacher B, Breitnebach V, Villa LL, Prolla JC, Bozzetti MC. Identificação do papilomavírus humano por biología molecular em mulheres assintomáticas. Rev Saúde Pública 2002;36:59-100.

Flores Y, Shah K, Lazcano E, Hernández M, Bishai D, Ferris D, et al. Design and methods for the evaluation of an HPV-based cervical cancer screening strategy in México: the Morelos HPV Study. Salud pública Méx 2002;44:335-44.

Meijer CJ, Snijders PJ, van den Burle AJ. Screening for cervical cancer: shuold we test for infection with high-risk HPV? CMAJ 2000;163:535-8.

Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.

Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S, et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002;360:228-9.

Varghese C, Amma NS, Chitrathara K, Dhakad N, Rani P, Malathy L, et al. Risk factors for cervical dysplasia in Kerala, India. Bull World Health Organ 1999;77:281-3.

Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001;286:3106-14.

Bosch FX, Manos MM, Muñoz M, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (I BSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.

de San José S, Palacio V, Tafur LA, Vázquez S, Espitia VE, Vázquez F, et al. Prostitution, HIV, and cervical neoplasia: a survey in Spain and Colombia. Cancer Epidemiol Biomarkers Prev 1993;2:531-5.

Tran-Thanh D, Provecher D, Koushik A, Duarte-Franco E, Kessous A, Drouin P, et al. Herpes simplex virus type II is not a cofactor to human papillomavirus in cancer of the uterine cervix. Am J Obstet Gynecol 2003;188:129-34.

Munoz N, Kato I, Bosch FX, Eluf-Neto J, de San Jose S, Ascunce N, et al. Risk factor for HPV detection in middle-age women. Sex Transm Dis 1996;23:504-10.

Anttila T, Saikku P, Koskela P, Bloigu A, Dillner J, Ikaheimo I, et al. Serotypes of Chlamydia trachomatis and risk of development of cervical squamous cell carcinoma. JAMA 2001;285:47-51.

Ellerbrock TV, Chiasson MA, Bush TJ, Sun XW, Sawo D, Brudney K, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000; 283:1031-7.

Castañeda-Iñiguez MS, Toledo-Cisneros R, Aguilera-Delgadillo M. Factores de riesgo para cáncer cervicouterino en mujeres de Zacatecas. Salud Pública Méx 1998;40:330-8.

Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002;359:1093-101.

Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA 2000;284:706-12.

Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah KV, Walboomers JM, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002;359:1085-92.

Mohar A, Frías-Mendivil M, Suchil-Bernal L, Mora-Macías T, de la Garza JG. Epidemiología descriptiva del cáncer en el Instituto Nacional de Cancerología de México. Salud Pública Méx 1997;39:253-8.

Hasenyager C. Knowledge of cervical cancer screening among women attending a university health center. J Am Coll Health 1999;47:221-4.

Fernández ME, Tortolero-Luna G, Gold RS. Mammography and Pap test screening among low-income foreign-born Hispanic women in the USA. Cad Saúde Pública 1998; 14:133-47.

Lorant V, Boland B, Humblet P, Deliege D. Equity in prevention and health care. J Epidemiol Community Health 2002;56:510-6.

Benia W, Tellecha G. Estudio de los factores de riesgo para cáncer de mama y cuello uterino en mujeres usuarias de tres policlínicas barriales de Montevideo: 1997. Rev Med Uruguay 2000;16:101-16.

Lindau ST, Tomori C, Lyons T, Langseth L, Benett CL, Garcia P. The association of heath literacy with cervical cancer prevention knowledge and health behaviors in multiethnic cohort women. Am J Obstet Gynecol 2002;186:938-43.

McKee MD, Lurio J, Marantz P, Burton W, Mulvihill M. Barriers to follow-up of abnormal Papanicolau smears in an urban community health center. Arch Fam Med 1999;8:129-34.

Marteau TM, Senior V, Sasieni P. Women`s understanding of a "normal smear test result": experimental questionnaire based study. BMJ 2001;322:526-8.

Hewitt M, Devesa S, Breen N. Papanicolau test use among reproductive-age women at high risk for cervical cancer: analyses of the 1995 National Survey of Family Growth. Am J Public Health 2002;92:666-9.

Aguilar-Pérez JA, Leyva-López AG, Angulo-Nájera D, Salinas A, Lazcano-Ponce EC. Tamizaje de cáncer cervical: conocimiento de la utilidad y uso de citología cervical en México. Rev Saúde pública 2003;37:100-6.

Lamadrid S. Aspectos socio-culturales de la sexualidad como factores obstaculizantes de la prevención secundaria del cáncer cérvico uterino. Cad Saúde Púb 1998;14 Sup 1:33-40.

Lazcano-Ponce EC, Rascon-Pacheco RA, Lozano-Ascencio R, Velasco-Mondragón HE. Mortality from carcinoma of the uterine cervix in México. Acta Cytol 1996;40:506-12.

Lazcano-Ponce EC, Alonso de Ruiz P, Lopez-Carrillo L, Najera-Aguilar P, Avila-Ceniceros R, Escandon-Romero C, et al. Validity and reproducibility of cytologic diagnosis in a sample of cervical cancer screening centers in Mexico. Acta Cytol 1997;41:227-84.

República de Colombia. Ministerio de Salud. Decreto 2309 de Octubre 15 de 2002.

Arillo-Santillán E, Lazcano-Ponce E, Peris M, Salazar-Martínez E, Salomón-Castro J, Alonso-De Ruiz P. El conocimiento de profesionales de la salud sobre la prevención del cáncer cervical. Alternativas de educación médica. Salud Pública Méx 2000;42:34-42.

Tovar-Guzman V, Hernández-Giron C, Lazcano-Ponce E, Romineu I, Hernández M. Breast cancer in Mexican women: an epidemiological study with cervical cancer control. Rev Saúde Pública 2000;24:113-9.

Pinho AA, de Mattos MC. Validade da citologia cervicovaginal na detecção de lesões pré-neoplásicas e neoplásicas de colo de útero. J Brasil Patol Med Lab 2002;38:225-31.

Sawaya GF, Brown AD, Washington AE, Garber AM. Clinical practice. Current approaches to cervical-cancer screening. N Eng J Med 2001;344:1603-7.

Sherlaw-Johnson C, Gallivan S, Jenkins D. Withdrawing low risk women from cervical screening programmes: mathematical modeling study. BMJ 1999;318:356-61.

Selvaggi SM. Implications of low diagnostic reproducibility of cervical cytologic and histologic diagnosis. JAMA 2001;285:1506-7.

Pinto AP, Tulio S, Cruz OR. Co-factores do HPV na oncogênese cervical. Rev Assoc Med Brasil 2002;48:73-8.

Adad SJ, Souza MAH, Etchebehere RM, Sandanha JC, Falco VAA, Murta EFC. Cyto-histological correlation of 219 patients submitted to surgical treatment due to diagnosis of cervical intraepithelial neoplasia. S Paulo Med J 1999;117:81-4.

Stoler MH, Schiffman M. Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytology and histologic interpretations. Realistic estimates from the USCUS-LSIL Triage Study. JAMA 2001;285:1500-5.

Miller AB. Failures of cervical cancer screening. Am J Public Health 1995;85:761.

Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.

Stoler MH. New Bethesda terminology and evidence-based management guidelines for cervical cytology findings. JAMA 2002;287:2140-1.

Cannistra SA, Niloff JM. Cancer of the uterine cervix. N Eng J Med 1996;334:1030-7.

Lonky NM, Sadeghi M, Tsadik GW, Petitti D. The clinical significance of the poor correlation of cervical dysplasia and cervical malignancy with referral cytologic results. Am J Obstet Gynecol 1999;181:560-6.

Parashari A, Singh V, Sehgal A, Satyanarayana L, Sodhani P, Gupta MM. Low-cost technology for screening uterine cervical cancer. Bull World Health Organ 2000;78:964-7.

Organización Panamericana de la Salud. Prevención clínica. Guía para médicos. Publicación científica Nº 568. Washington: OPS; 1998.

University of Zimbabwe/JHPIEGO Cervical Cancer Project. Visual inspection with acetic acid for cervical-cancer screening: test qualities in a primary-care setting. Lancet 1999;353:869-73.